BCAX
Bicara Therapeutics Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
-20/100
Last price
16.56
▼ 0.73 (4.22%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
15.90
Prev close
17.29
Day high
17.52
Day low
16.33
Volume
981.20K
Market cap
$1.10B
P/E (TTM)
—
52W range
13.70 – 30.99
Day trading desk
Gap from prior close
-8.04%
Prior close 17.29
VWAP
16.60
-0.24% from price
Relative volume
1.45×
Normal
Session range
12.89%
15.90 – 17.95
Position in range
32%
Mid range
ATR (14D)
1.18
7.14% of price
Prior day high
19.12
PDH
Prior day low
17.13
PDL
Bid / ask spread
—
Quote not published
Session volume
875.19K
Avg 603.81K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-10.78%
-12.7%
1M
-28.53%
-29.7%
3M
-42.88%
-47.4%
6M
-22.22%
-40.4%
YTD
-1.60%
-15.9%
1Y
-2.82%
-19.2%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BCAX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-11.74K
Net selling
Buy transactions
14
192.66K shares
Sell transactions
14
204.40K shares
Net transactions
+28
Buys less sells
Sell : buy shares
1.1 : 1
Mixed
Insider-held shares
6.66M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 8, 26 | COHLHEPP RYAN Chief Executive Officer |
SELL | 17.50K | $400.72K | Direct |
| Sep 8, 26 | COHLHEPP RYAN Chief Executive Officer |
CONVERSION | 17.50K | $66.32K | Direct |
| Aug 10, 26 | COHLHEPP RYAN President |
SELL | 18.75K | $524.53K | Direct |
| Aug 10, 26 | COHLHEPP RYAN President |
CONVERSION | 18.75K | $71.06K | Direct |
| Aug 10, 26 | MAZUMDAR CLAIRE Chief Executive Officer |
SELL | 10.00K | $279.75K | Direct |
| Aug 10, 26 | MAZUMDAR CLAIRE Chief Executive Officer |
CONVERSION | 10.00K | $37.90K | Direct |
| Aug 10, 26 | HYEP IVAN Chief Financial Officer |
SELL | 12.50K | $349.59K | Direct |
| Aug 10, 26 | HYEP IVAN Chief Financial Officer |
CONVERSION | 12.50K | $47.37K | Direct |
| Jul 10, 26 | MAZUMDAR CLAIRE Chief Executive Officer |
SELL | 10.00K | $284.20K | Direct |
| Jul 10, 26 | MAZUMDAR CLAIRE Chief Executive Officer |
CONVERSION | 10.00K | $37.90K | Direct |
| Jul 9, 26 | COHLHEPP RYAN President |
SELL | 28.75K | $833.13K | Direct |
| Jul 8, 26 | COHLHEPP RYAN President |
CONVERSION | 18.75K | $71.06K | Direct |
| Jul 8, 26 | HYEP IVAN Chief Financial Officer |
SELL | 28.00K | $807.67K | Direct |
| Jul 8, 26 | HYEP IVAN Chief Financial Officer |
CONVERSION | 12.50K | $47.37K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
COHLHEPP RYAN |
Chief Executive Officer | 181.64K | Sale |
HYEP IVAN |
Chief Financial Officer | 129.85K | Sale |
MAZUMDAR CLAIRE |
Chief Executive Officer | 362.15K | Sale |
MEISNER LARA S. |
Officer | 0 | Sale |
RA CAPITAL MANAGEMENT, L.P. |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
RABEN DAVID M.D. |
Officer | 55.29K | Sale |
Fundamentals
Market cap$1.10B
Enterprise value$599.73M
Revenue (TTM)—
Gross profit—
EBITDA$-201.83M
Net income$-185.36M
EPS (TTM)$-2.95
Free cash flow$-76.95M
Total cash$497.26M
Total debt$1.16M
Book value / share$7.11
Shares outstanding66.17M
Float36.90M
Short % of float23.56%
Dividend yield0.00%
Beta (5Y)-0.69
Valuation & profitability ratios
Trailing P/E—
Forward P/E-4.71
PEG ratio—
Price / sales—
Price / book2.33
EV / revenue—
EV / EBITDA-2.97
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-41.01%
Return on assets-26.14%
Debt / equity0.25
Current ratio11.59
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $125.10M | $63.62M | $30.62M | $31.31M | +96.6% |
| Selling, general & admin | $30.51M | $18.77M | $9.27M | $6.34M | +62.5% |
| Total operating expense | $155.60M | $82.39M | $39.89M | $37.66M | +88.9% |
| Operating income | -$155.60M | -$82.39M | -$39.89M | -$37.66M | -88.9% |
| Net interest income | $17.87M | $14.58M | $1.31M | -$108.00K | +22.6% |
| Pre-tax income | -$137.73M | -$67.81M | -$51.98M | -$37.84M | -103.1% |
| Tax provision | $217.00K | $187.00K | $5.00K | $1.00K | +16.0% |
| Net income | -$137.95M | -$68.00M | -$51.98M | -$37.84M | -102.9% |
| Net income to common | -$137.95M | -$68.00M | -$51.98M | -$37.84M | -102.9% |
| Basic EPS | -2.52 | -4.05 | -1.53 | -2.45 | +37.8% |
| Diluted EPS | -2.52 | -4.05 | -1.53 | -2.45 | +37.8% |
| EBIT | -$155.60M | -$82.39M | -$39.89M | -$37.73M | -88.9% |
| EBITDA | -$155.50M | -$82.33M | -$39.87M | -$37.72M | -88.9% |
| Basic shares | 54.68M | 16.81M | 33.98M | 15.44M | +225.4% |
| Diluted shares | 54.68M | 16.81M | 33.98M | 15.44M | +225.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $96.69M | $489.71M | $230.44M | $4.16M | -80.3% |
| Cash & short-term investments | $414.80M | $489.71M | $230.44M | $4.16M | -15.3% |
| Total current assets | $422.05M | $502.53M | $231.07M | $4.98M | -16.0% |
| Property, plant & equipment | $2.03M | $845.00K | $815.00K | $636.00K | +140.4% |
| Total assets | $430.99M | $510.00M | $233.98M | $6.70M | -15.5% |
| Total current liabilities | $28.95M | $17.99M | $15.09M | $23.90M | +60.9% |
| Total debt | $1.71M | $738.00K | $657.00K | $0 | +131.7% |
| Total liabilities | $29.54M | $18.12M | $382.75M | $105.51M | +63.0% |
| Retained earnings | -$358.97M | -$221.02M | -$153.02M | -$101.04M | -62.4% |
| Shareholder equity | $401.45M | $491.88M | -$148.77M | -$98.80M | -18.4% |
| Working capital | $393.10M | $484.54M | $215.99M | -$18.91M | -18.9% |
| Net tangible assets | $401.45M | $491.88M | -$148.77M | -$98.80M | -18.4% |
| Shares issued | 56.60M | 54.44M | 51.76M | 51.76M | +4.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$137.95M | -$68.00M | -$51.98M | -$37.84M | -102.9% |
| Depreciation & amortisation | $105.00K | $56.00K | $19.00K | $10.00K | +87.5% |
| Stock-based compensation | $15.01M | $7.40M | $1.90M | $810.00K | +102.9% |
| Change in working capital | $14.81M | -$14.13M | -$9.62M | $4.95M | +204.8% |
| Operating cash flow | -$106.83M | -$74.75M | -$45.63M | -$32.08M | -42.9% |
| Capital expenditure | -$280.00K | -$71.00K | -$586.00K | -$192.00K | -294.4% |
| Investing cash flow | -$318.45M | -$9.00K | -$586.00K | -$192.00K | -3,538,266.7% |
| Financing cash flow | $32.26M | $334.03M | $272.50M | $31.70M | -90.3% |
| Free cash flow | -$107.11M | -$74.82M | -$46.21M | -$32.27M | -43.2% |
| End cash position | $96.69M | $489.71M | $230.44M | $4.16M | -80.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $45.77M | $47.50M | $32.99M | $32.98M | $24.80M | -3.6% |
| Selling, general & admin | $14.18M | $12.74M | $8.13M | $7.70M | $7.22M | +11.3% |
| Total operating expense | $59.95M | $60.24M | $41.12M | $40.68M | $32.02M | -0.5% |
| Operating income | -$59.95M | -$60.24M | -$41.12M | -$40.68M | -$32.02M | +0.5% |
| Net interest income | $4.58M | $4.08M | $3.79M | $4.39M | $4.68M | +12.1% |
| Pre-tax income | -$55.38M | -$56.16M | -$37.33M | -$36.29M | -$27.34M | +1.4% |
| Tax provision | $61.00K | $52.00K | $53.00K | $40.00K | $52.00K | +17.3% |
| Net income | -$55.44M | -$56.21M | -$37.39M | -$36.33M | -$27.39M | +1.4% |
| Net income to common | -$55.44M | -$56.21M | -$37.39M | -$36.33M | -$27.39M | +1.4% |
| Basic EPS | -0.82 | -0.93 | -0.68 | -0.67 | -0.50 | +11.8% |
| Diluted EPS | -0.82 | -0.93 | -0.68 | -0.67 | -0.50 | +11.8% |
| EBIT | -$59.95M | -$60.24M | -$41.12M | -$40.68M | -$32.02M | +0.5% |
| EBITDA | -$59.91M | -$60.20M | -$41.08M | -$40.65M | -$32.00M | +0.5% |
| Basic shares | 67.93M | 60.72M | 55.14M | 54.56M | 54.54M | +11.9% |
| Diluted shares | 67.93M | 60.72M | 55.14M | 54.56M | 54.54M | +11.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $96.60M | $323.46M | $96.69M | $171.67M | $436.61M | -70.1% |
| Cash & short-term investments | $497.26M | $539.75M | $414.80M | $290.17M | $436.61M | -7.9% |
| Total current assets | $503.82M | $544.91M | $422.05M | $297.37M | $444.39M | -7.5% |
| Property, plant & equipment | $1.51M | $1.77M | $2.03M | $2.10M | $2.35M | -14.7% |
| Total assets | $512.24M | $553.60M | $430.99M | $424.69M | $453.59M | -7.5% |
| Total current liabilities | $43.48M | $39.34M | $28.95M | $21.03M | $17.23M | +10.5% |
| Total debt | $1.16M | $1.44M | $1.71M | $1.98M | $2.24M | -19.3% |
| Total liabilities | $43.48M | $39.64M | $29.54M | $21.91M | $18.39M | +9.7% |
| Retained earnings | -$470.61M | -$415.18M | -$358.97M | -$321.58M | -$285.25M | -13.4% |
| Shareholder equity | $468.77M | $513.96M | $401.45M | $402.78M | $435.20M | -8.8% |
| Working capital | $460.35M | $505.57M | $393.10M | $276.34M | $427.16M | -8.9% |
| Net tangible assets | $468.77M | $513.96M | $401.45M | $402.78M | $435.20M | -8.8% |
| Shares issued | 65.55M | 65.55M | 56.60M | 54.61M | 54.56M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$55.44M | -$56.21M | -$37.39M | -$36.33M | -$27.39M | +1.4% |
| Depreciation & amortisation | $44.00K | $44.00K | $43.00K | $24.00K | $19.00K | 0.0% |
| Stock-based compensation | $8.24M | $5.86M | $4.45M | $3.61M | $3.49M | +40.6% |
| Change in working capital | $2.43M | $12.19M | $8.44M | $3.16M | -$1.93M | -80.0% |
| Operating cash flow | -$44.21M | -$37.51M | -$23.89M | -$29.25M | -$25.59M | -17.9% |
| Capital expenditure | -$60.00K | -$60.00K | -$238.00K | — | — | 0.0% |
| Investing cash flow | -$184.99M | $100.94M | -$82.33M | -$236.12M | $0 | -283.3% |
| Financing cash flow | $2.33M | $163.34M | $31.23M | $436.00K | $135.00K | -98.6% |
| Free cash flow | -$44.27M | -$37.57M | -$24.12M | -$29.29M | -$25.59M | -17.8% |
| End cash position | $96.60M | $323.46M | $96.69M | $171.67M | $436.61M | -70.1% |
Options analytics
Put / call volume
0.05
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
35.00
+111.4% from spot
ATM implied vol
25.0%
Nearest strike to spot
Skew (10% OTM)
+25.0%
Puts bid over calls
Call volume
234
Contracts, this expiry
Put volume
11
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
30.00
1 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.83 | -0.82 | +0.6% |
| Mar 2026 | -0.65 | -0.93 | -42.6% |
| Dec 2025 | -0.65 | -0.68 | -4.0% |
| Sep 2025 | -0.53 | -0.67 | -25.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.82 | 12 | $0 | 0.0% |
| Next quarter | -0.85 | 12 | $0 | 0.0% |
| Current year | -3.39 | 12 | $0 | 0.0% |
| Next year | -3.52 | 11 | $0 | 0.0% |
Analyst targets & ownership
Mean target$35.50
High target$45.00
Low target$20.00
Implied upside114.37%
Analyst count12
ConsensusSTRONG BUY
Strong buy / Buy3 / 10
Hold1
Sell / Strong sell0 / 0
Held by insiders10.07%
Held by institutions107.64%
Institutions holding240
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
18.51
-10.55% from price
SMA 20
20.63
-19.72% from price
SMA 50
23.23
-28.71% from price
SMA 100
23.84
-30.54% from price
SMA 200
21.30
-22.26% from price
EMA 12
18.92
-12.48% from price
EMA 26
20.72
-20.07% from price
EMA 50
22.24
-25.56% from price
RSI (14)
20.6
Oversold
MACD (12,26,9)
-1.80
Hist -0.34
ATR (14)
1.18
7.14% of price
Realised vol 30D
45.7%
Annualised
Bollinger upper
25.19
20, 2σ
Bollinger lower
16.07
20, 2σ
50 / 200 cross
Golden
23.23 vs 21.30
Trend bias
Below 200
-22.26%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.88
Less volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
45.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-45.5%
Peak to trough
Max drawdown 5Y
-67.8%
Peak to trough
ATR 14
1.18
7.14% of price
Beta (reported)
-0.69
5Y monthly, from filing
Short interest
Shares short
11.19M
Prior 10.46M
Change vs prior
+7.0%
Shorts adding
% of float
23.56%
Heavily shorted
% of shares out
16.91%
Against total outstanding
Days to cover
22.4
Crowded exit
Float
36.90M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 19, 26 | BMO Capital | INITIATED | — | Outperform |
| Aug 12, 26 | Goldman Sachs | MAINTAINED | Neutral | Neutral |
| Aug 12, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Aug 12, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Aug 12, 26 | Mizuho | MAINTAINED | Neutral | Neutral |
| Aug 12, 26 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Aug 12, 26 | BTIG | MAINTAINED | Buy | Buy |
| May 12, 26 | Goldman Sachs | MAINTAINED | Neutral | Neutral |
| May 12, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| May 11, 26 | Guggenheim | INITIATED | — | Buy |
| Mar 31, 26 | Goldman Sachs | MAINTAINED | Neutral | Neutral |
| Mar 31, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-25
Offering Registrations
S-8 · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-07-28
Corporate Changes & Voting Matters
8-K · 2026-06-10
Corporate Changes & Voting Matters
8-K · 2026-05-21
Corporate Changes & Voting Matters
8-K · 2026-05-11
Annual Report to Shareholders
ARS · 2026-04-27
Offering Registrations
S-8 · 2026-03-31
Headlines
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 2d ago
Pliant Therapeutics Appoints David Raben as Chief Medical Officer
MT Newswires · 6d ago
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 34d ago
Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul
Insider Monkey · 49d ago
BMO Capital Initiates Bicara Therapeutics at Outperform
MT Newswires · 49d ago
Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript
Motley Fool · 50d ago
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 54d ago
Leadership Shake-Up And Ficerafusp Alfa Milestone Timeline Might Change The Case For Investing In Bicara Therapeutics (BCAX)
Simply Wall St. · 55d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.